Premarin (conjugated estrogens)

September 26, 2002

Audience: Reproductive healthcare professionals

FDA and Wyeth notified healthcare professionals about safety related labeling changes to the INDICATIONS and USAGE, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, and DOSAGE and ADMINISTRATION sections of the labels. The new safety information reflects new data, primarily from the Women's Health Initiative (WHI).

View comments

Hide
(web5)